All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

WHO releases blueprint to help nations combat growing fungal disease threat and antifungal resistance

By

Chris Dall, MA

3d ago· 6 min readenNews

Summary

The World Health Organization (WHO) has released a new "blueprint" to help countries address the growing threat of fungal infections and antifungal resistance. The document provides a framework for strengthening national and regional responses to fungal diseases, which affect over 300 million people annually but remain under-recognized, underdiagnosed, and poorly managed. While some fungal infections are easily treatable, the WHO is particularly concerned about invasive infections caused by fungal species that have developed high resistance to limited treatment options.

Source

bskyWHO releases blueprint to help nations combat growing fungal disease threat and antifungal resistancecidrap.umn.edu

Key quotes

· 3 pulled
The World Health Organization (WHO) has released a new 'blueprint' to help countries respond to the growing threat of fungal infections and antifungal resistance.
The document provides a framework to strengthen national and regional responses to fungal diseases, which affect more than 300 million people each year yet remain widely under-recognized, underdiagnosed, and poorly managed.
Of particular concern are the invasive infections caused by fungal species that have become highly resistant to the limited treatment options available.
Snippet from the RSS feed
The World Health Organization (WHO) has released a new “blueprint” to help countries respond to the growing threat of fungal infections and antifungal resistance.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.